clinically relevant

Related by string. Clinically Relevant * Clinically : patented clinically proven . demonstrated clinically meaningful . clinically obese . clinically proven . clinically depressed . clinically validated / Relevant . RELEVANT . rele vant : AND OTHER RELEVANT POLICIES . Trigger Relevant Expiry Date . Relevant Expiry Date . Cautionary Statement Relevant . culturally relevant * *

Related by context. Frequent words. (Click for all words.) 71 clinically meaningful 61 pharmacodynamic 58 pharmacologic 58 clinically 58 physiologic 57 tolerability 57 pharmacological 57 prespecified 56 thromboembolic events 56 antitumor activity 56 echocardiographic 56 dose limiting toxicities 55 genotypic 55 #ME# 55 tolerability profile 55 decitabine 55 biomarker 55 primary endpoint 55 Secondary endpoints include 55 statistically significant 55 clinical 55 pharmacokinetic 55 Pharmacokinetic 55 adalimumab 55 histologic 55 immunologic 54 secondary endpoints 54 efficacy 54 aetiology 54 comorbid conditions 54 secondary endpoint 54 biomarkers 54 PXD# 54 neuroprotection 54 Secondary endpoints included 54 reproducible 54 platelet function 54 mg dose 54 hypercalcemia 54 antiplatelet 54 disease progression 53 antithrombotic 53 pharmacodynamics 53 etanercept 53 evaluable 53 statistically significant improvement 53 clinical endpoints 53 symptom severity 53 ticagrelor 53 efficacy endpoints 53 limiting toxicity 53 neurophysiological 53 statistical significance 53 Clinically 53 calcitonin 53 TRIOLEX 53 thromboembolism 53 laboratory abnormalities 53 Secondary endpoints 53 pathologic 53 anticoagulation 53 tocilizumab 53 vivo 53 statistically significant reduction 53 myocardial ischemia 53 talactoferrin 53 FDG PET 53 neoplastic 53 immunomodulatory 53 congenital anomalies 53 monotherapy 53 hemodynamic 52 tumor regression 52 sustained virologic response 52 comorbidities 52 belimumab 52 insulin glargine 52 composite endpoint 52 elagolix 52 statistically significant p 52 teriparatide 52 dosing regimens 52 tumor shrinkage 52 LEVADEX 52 achieve statistical significance 52 ZYBRESTAT 52 statistically significant differences 52 imetelstat 52 immunological 52 hypercholesterolemia 52 CoFactor 52 phenotypic 52 diabetic neuropathic pain 52 LymphoStat B 52 antihypertensive drugs 52 hematologic 52 primary efficacy endpoint 52 Phase 2a trial 52 randomized clinical trials 51 valsartan 51 tiotropium

Back to home page